Adolor feels the pain

Adolor Corp. said Thursday it plans to disband its sales force of 35 people and eliminate 17 other positions because of delays in getting approval for its lead new drug candidate.

The Exton, Pa., biopharmaceutical company established its sales force early last year in anticipation of launching Entereg, its experimental treatment for the management of postoperative ileus -- a bowel disorder commonly experienced by patients after surgery.

Overall, the number of Adolor employees will be reduced to 128 from 180.